Skip to main content
. 2016 Mar 16;11(7):767–781. doi: 10.2217/nnm.16.14

Figure 6. . Targeting efficiency.

Figure 6. 

Ratio (expressed in%) + SE of tumor exposure versus plasma exposure (A) or versus the sum of nontarget organs exposure (liver, kidney, spleen, heart, lung) for A549-WT and A549-DDP tumor models, after IV injection of NTG and TG nanoparticles at 3 mg/kg equivalent siRNA.

n = 5 mice.

*p < 0.05; **p < 0.01; ***p < 0.001 (t-test TG vs NTG).

DDP: Cisplatin; NTG: Nontargeted; SE: standard error; TG: Targeted.